Literature DB >> 23606931

Safety and efficacy of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukaemia.

Martin J S Dyer1.   

Abstract

There are now many therapeutic CD20 monoclonal antibodies undergoing clinical trials for B-cell malignancy and autoimmune conditions; which is optimal for cancer therapy is not clear. The novel human IgG1 CD20 monoclonal antibody ofatumumab has shown significant activity in difficult to treat patients with chronic lymphocytic leukemia, namely those resistant or refractory to fludarabine and alemtuzumab and has now been licensed for this uncommon indication. This brief review summarizes the clinical data obtained with ofatumumab in CLL in terms of both efficacy and toxicity.

Entities:  

Keywords:  CD20; chronic lymphocytic leukemia; ofatumumab; therapeutic monoclonal antibodies

Year:  2012        PMID： 23606931      PMCID： PMC3627333          DOI： 10.1177/2040620712445329

Source DB:  PubMed          Journal:  Ther Adv Hematol        ISSN： 2040-6207


  52 in total

1.  Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia.

Authors:  William G Wierda; Thomas J Kipps; Jan Dürig; Laimonas Griskevicius; Stephan Stilgenbauer; Jirí Mayer; Lukás Smolej; Georg Hess; Rasa Griniute; Francisco J Hernandez-Ilizaliturri; Swaminathan Padmanabhan; Michele Gorczyca; Chai-Ni Chang; Geoffrey Chan; Ira Gupta; Tina G Nielsen; Charlotte A Russell
Journal:  Blood       Date:  2011-04-15       Impact factor: 22.113

2.  The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.

Authors:  Lee A Honigberg; Ashley M Smith; Mint Sirisawad; Erik Verner; David Loury; Betty Chang; Shyr Li; Zhengying Pan; Douglas H Thamm; Richard A Miller; Joseph J Buggy
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-06       Impact factor: 11.205

3.  Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997.

Authors:  Mitchell R Smith; Donna Neuberg; Ian W Flinn; Michael R Grever; Hillard M Lazarus; Jacob M Rowe; Gordon Dewald; John M Bennett; Elisabeth M Paietta; John C Byrd; Mohamad A Hussein; Frederick R Appelbaum; Richard A Larson; Mark R Litzow; Martin S Tallman
Journal:  Blood       Date:  2011-07-29       Impact factor: 22.113

4.  Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study.

Authors:  William G Wierda; Swaminathan Padmanabhan; Geoffrey W Chan; Ira V Gupta; Steen Lisby; Anders Osterborg
Journal:  Blood       Date:  2011-08-19       Impact factor: 22.113

Review 5.  Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.

Authors:  A J Grillo-López; C A White; C Varns; D Shen; A Wei; A McClure; B K Dallaire
Journal:  Semin Oncol       Date:  1999-10       Impact factor: 4.929

6.  Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia.

Authors:  Michael E Williams; John J Densmore; Andrew W Pawluczkowycz; Paul V Beum; Adam D Kennedy; Margaret A Lindorfer; Susan H Hamil; Jane C Eggleton; Ronald P Taylor
Journal:  J Immunol       Date:  2006-11-15       Impact factor: 5.422

7.  Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma.

Authors:  K Tobinai; T Igarashi; K Itoh; Y Kobayashi; M Taniwaki; M Ogura; T Kinoshita; T Hotta; K Aikawa; K Tsushita; A Hiraoka; Y Matsuno; S Nakamura; S Mori; Y Ohashi
Journal:  Ann Oncol       Date:  2004-05       Impact factor: 32.976

8.  Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival.

Authors:  Nathalie A Johnson; Merrill Boyle; Ali Bashashati; Stephen Leach; Angela Brooks-Wilson; Laurie H Sehn; Mukesh Chhanabhai; Ryan R Brinkman; Joseph M Connors; Andrew P Weng; Randy D Gascoyne
Journal:  Blood       Date:  2008-11-24       Impact factor: 22.113

9.  Inactivating mutations of acetyltransferase genes in B-cell lymphoma.

Authors:  Laura Pasqualucci; David Dominguez-Sola; Annalisa Chiarenza; Giulia Fabbri; Adina Grunn; Vladimir Trifonov; Lawryn H Kasper; Stephanie Lerach; Hongyan Tang; Jing Ma; Davide Rossi; Amy Chadburn; Vundavalli V Murty; Charles G Mullighan; Gianluca Gaidano; Raul Rabadan; Paul K Brindle; Riccardo Dalla-Favera
Journal:  Nature       Date:  2011-03-10       Impact factor: 49.962

10.  Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.

Authors:  D Catovsky; S Richards; E Matutes; D Oscier; Mjs Dyer; R F Bezares; A R Pettitt; T Hamblin; D W Milligan; J A Child; M S Hamilton; C E Dearden; A G Smith; A G Bosanquet; Z Davis; V Brito-Babapulle; M Else; R Wade; P Hillmen
Journal:  Lancet       Date:  2007-07-21       Impact factor: 79.321
View more
  2 in total

1.  Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin.

Authors:  Zhao Hui Li; Qian Zhang; Hai Bin Wang; Ya Nan Zhang; Ding Ding; Li Qiang Pan; David Miao; Shi Xu; Chen Zhang; Pei Hua Luo; Hua Naranmandura; Shu Qing Chen
Journal:  Invest New Drugs       Date:  2013-08-01       Impact factor: 3.850

Review 2.  Sequencing of chronic lymphocytic leukemia therapies.

Authors:  Jacqueline C Barrientos
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.